Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 3994-3999

  Djimdé, Abdoulaye A ^a   Tekete, Mamadou ^a,h   Abdulla, Salim ^b   Lyimo, John ^b   Bassat, Quique ^c,d   Mandomando, Inacio ^d,e   Lefèvre, Gilbert ^f   Borrmann, Steffen ^g,h  

^a UNIVERSITY OF BAMAKO   (Mali)

^b IFAKARA HEALTH INSTITUTE   (Tanzania)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Ministérioda Saúde   (Mozambique)

^e INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^f NOVARTIS PHARMA AG   (Switzerland)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ;

ANTIMICROBIAL THERAPY; ANTIPROTOZOAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BENIN; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MALI; MAXIMUM PLASMA CONCENTRATION; MOZAMBIQUE; MULTICENTER STUDY; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET FORMULATION; TANZANIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE;

EID: 80051821572     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01115-10     Document Type: Article

References (26)

1. Abdulla, S., et al. 2008. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: A randomised, single-blind, multicentre trial. Lancet 372:1819-1827.
2. Ashley, E A, and N J White. 2005. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18:531-536. (Pubitemid 41634767)
3. Ashley, E A, et al. 2007. Pharmacokinetic study of artemether- lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health 12:201-208.
4. Bindschedler, M., et al. 2000. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur. J. Clin. Pharmacol. 56:375-381.
5. Borrmann, S., et al. 2010. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®) for acute uncomplicated Plasmodium falciparum malaria. Trop. Med. Int. Health 15:434-441.
6. Duffy, P E, and T K Mutabingwa. 2006. Artemisinin combination therapies. Lancet 367:2037-2039.
7. Ezzet, F., M. Van Vugt, F. Nosten, S. Looareesuwan, and N J White. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704. (Pubitemid 30117964)
8. Ezzet, F., R. Mull, and J. Karbwang. 1998. Population pharmacokinetics and therapeutic response of CGP56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561. (Pubitemid 28522119)
9. Federal Register. 2005. ICH E14 guidance. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed. Regist. 70:61134-61135.
10. Hietala, S F, et al. 2010. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob. Agents Chemother. 54:4780-4788.
11. Jansen, F H, et al. 2007. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. Am. J. Trop. Med. Hyg. 77:1005-1009. (Pubitemid 351837783)
12. Karunajeewa, H A, et al. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
13. Kokwaro, G., L. Mwai, and A. Nzila. 2007. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin. Pharmacother. 8:75-94. (Pubitemid 46070831)
14. Lefèvre, G., et al. 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 64:247-256.
15. Makanga, M., et al. 2006. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: A pooled analysis of individual patient data. Am. J. Trop. Med. Hyg. 74:991-998. (Pubitemid 351627405)
16. McGready, R., et al. 2008. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 5:e253.
17. Mueller, E A, et al. 2006. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: A pooled analysis of individual patient data from randomized clinical trials. Acta Trop. 100:41-53. (Pubitemid 44830005)
18. Mutabingwa, T K 2005. Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy! Acta Trop. 95:305-315. (Pubitemid 41207297)
19. Mwesigwa, J., et al. 2010. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob. Agents Chemother. 54:52-59.
20. Nosten, F, and N J White. 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(6 Suppl.):181-192.
21. Piola, P., et al. 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: A randomised trial. Lancet 365:1467-1473. (Pubitemid 40591691)
22. Price, R N, et al. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42:1570-1577.
23. Simpson, J A, et al. 2006. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med. 3:e444.
24. Souppart, C., N. Gauducheau, N. Sandrenan, and F. Richard. 2002. Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 774:195-203. (Pubitemid 34655491)
25. Van Vugt, M., et al. 1999. No evidence of cardiotoxicity during anti-malarial treatment with artemether-lumefantrine. Am. J. Trop. Med. Hyg. 61:964-967. (Pubitemid 30084122)
26. World Health Organization. 2009. World malaria report 2009. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2009/ 9789241563901-eng.pdf (accessed May 12, 2011).